Abstract

Discarding drug-candidates with potential metabolism issues or with significant drug-drug interactions (DDI) is of major importance in drug discovery projects. When a compound is metabolized by catalytic enzymes, especially CYP450 3A4, the risk of DDI is potentially high. [1] An important point in the ADME studies is the characterization of the enzymes involved in the metabolism of drugs. Among these enzymes, the human cytochrome P450 family (CYP), more specifically 1A2, 2C’s, 2D6 and 3A4, are the most intensively studied [2] and QSAR approaches have shown to be valuable for prediction studies. [3] In many of these stud

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.